> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cipla Cited on Recent Inspection Findings in Form 483
- URL: https://www.fdaweb.com/cipla-cited-on-recent-inspection-findings-in-form-483/
- Published: 2018-03-27T12:00:00.000Z
- Updated: 2026-09-14T23:55:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141073

A recent inspection of a Cipla drug manufacturing plant in Goa, India has documented significant GMP violations. According to a [just-posted Form 483](https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM602817.pdf?ref=fdaweb.com) from a 1/22-25 inspection, the firm failed to thoroughly review out-of specification results and in-process test failures. The inspection also revealed that Cipla’s batch records were incomplete because they did not identify a sampling plan or acceptance criteria for finished products. Additionally, the Form 483 cited the firm for incomplete laboratory records. For example, employees were not documenting lab error on test data sheets, the form says.